PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma

Journal of Nuclear Medicine

Volumn 53, Issue 2, 2012, Pages 182-190

  Van Kruchten, Michel ^a   Glaudemans, Andor W J M ^a   De Vries, Erik F J ^a   Beets Tan, Regina G H ^b   Schröder, Carolien P ^a   Dierckx, Rudi A ^a   De Vries, Elisabeth G E ^a   Hospers, Geke A P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FES PET; Breast cancer; Clinical value; Estrogen receptor; Imaging

Indexed keywords

16ALPHA FLUOROESTRADIOL F 18; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE LESION; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; LIVER INJURY; LIVER METASTASIS; MALE; MEDICAL SPECIALIST; METASTASIS POTENTIAL; NUCLEAR MEDICINE; ONCOLOGIST; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; RADIODIAGNOSIS; RETROSPECTIVE STUDY; VALIDATION PROCESS;

ADULT; AGED; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES;

EID: 84856790756     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.092734     Document Type: Article

References (33)

1. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; based on November 2009 SEER data submission. 2010. Available from: http://seer.cancer.gov. Accessed December 9, 2011.
2. Blamey RW, Hornmark-Stenstam B, Ball G, et al. ONCOPOOL: a European database for 16,944 cases of breast cancer. Eur J Cancer. 2010;46:56-71.
3. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168. (Pubitemid 28144151)
4. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481. (Pubitemid 29220854)
5. DeSombre ER, Thorpe SM, Rose C, et al. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res. 1986;46:4256s-4264s. (Pubitemid 16041245)
6. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: Limitations and potential. Oncologist. 2006;11:868-877. (Pubitemid 44373759)
7. Sharangpani GM, Joshi AS, Porter K, et al. Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer. J Microsc. 2007;226:244-255. (Pubitemid 47024246)
8. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-784.
10. Amir E, Clemons M, Freedman OC, et al. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies [abstract]. J Clin Oncol. 2010;28(suppl):1007.
11. Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20:1499-1504.
12. Karlsson E, Lindstrom LS, Wilking U, Skoog L, Johansson U, Bergh J. Discordance in hormone receptor status in breast cancer during tumor progression [abstract]. J Clin Oncol. 2010;28(suppl):1009.
13. NCCN Clinical Practice Guidelines in Clinical Oncology, version 2.2011. 2011. Available from: http://www.nccn.org/professionals/physician-gls/PDF/ breast.pdf. Accessed December 9, 2011.
14. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 (suppl)5:v15-19.
15. Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest. 2007;87:662-669. (Pubitemid 46920099)
16. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
17. Hospers GA, Helmond FA, de Vries EG, Dierckx RA, de Vries EF. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des. 2008;14:3020-3032.
18. 18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526-1531.
19. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48.
20. Peterson LM, Mankoff DA, Lawton T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med. 2008;49:367-374. (Pubitemid 351355201)
21. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803. (Pubitemid 32538187)
22. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-56. (Pubitemid 29137739)
23. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799. (Pubitemid 46630578)
24. 18F]fluoroestradiol. Appl Radiat Isot. 1996;47:395-399.
25. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging - version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
26. 18F- fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer. Thorax. 2003;58: 47-51.
27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
28. Oude Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast. 2009;18(suppl) 3:S66-S73.
29. Barentsz J, Takahashi S, Oyen W, et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol. 2006;24:3234-3244. (Pubitemid 46622064)
30. Layfield LJ, Saria E, Mooney EE, Liu K, Dodge RR. Tissue heterogeneity of immunohistochemically detected estrogen receptor: implications for image analysis quantification. Am J Clin Pathol. 1998;110:758-764. (Pubitemid 28541552)
31. van Netten JP, Algard FT, Coy P, et al. Heterogeneous estrogen receptor levels detected via multiple microsamples from individual breast cancers. Cancer. 1985;56:2019-2024. (Pubitemid 15240877)
32. 18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933-939.
33. 18F] fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 2001;42:679-684.